
Menu

Eureka Therapeutics Announces Positive Preliminary Results Of ET190L1 ARTEMIS™ T-Cell China Proof-Of-Concept Human Clinical Study In Relapsed And Refractory B-Cell Lymphoma At ASCO Annual Meeting
June 4, 2018
NO CYTOKINE RELEASE SYNDROME OBSERVED TO DATE EMERYVILLE, Calif., June 4, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of





Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies
January 22, 2018
EMERYVILLE, Calif., January 22, 2018 — Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing



